CY1117236T1 - Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 - Google Patents

Μονοκλωνικα αντισωματα εναντι γλυπικανης-3

Info

Publication number
CY1117236T1
CY1117236T1 CY20161100174T CY161100174T CY1117236T1 CY 1117236 T1 CY1117236 T1 CY 1117236T1 CY 20161100174 T CY20161100174 T CY 20161100174T CY 161100174 T CY161100174 T CY 161100174T CY 1117236 T1 CY1117236 T1 CY 1117236T1
Authority
CY
Cyprus
Prior art keywords
antibodies
glycican
methods
glypican
antibodies against
Prior art date
Application number
CY20161100174T
Other languages
English (en)
Inventor
Jonathan Alexander Terrett
Li-Sheng Lu
Haichun Huang
Dapeng Yao
Chin Pan
Heidi Leblanc
Timothy Sproul
Mark Yamanaka
Original Assignee
E. R. Squibb & Sons, L.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E. R. Squibb & Sons, L.L.C. filed Critical E. R. Squibb & Sons, L.L.C.
Publication of CY1117236T1 publication Critical patent/CY1117236T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Η παρούσα αποκάλυψη παρέχει απομονωθέντα μονοκλωνικά αντισώματα, ιδιαιτέρως ανθρώπινα μονοκλωνικά αντισώματα που συνδέονται ειδικώς προς Γλυπικάνη-3 με υψηλή συνάφεια. Επίσης παρέχονται μόρια νουκλεϊνικού οξέος που κωδικοποιούν αντισώματα Γλυπικάνης-3, φορείς έκφρασης, κύτταρα ξενιστές και μέθοδοι για έκφραση των αντισωμάτων Γλυπικάνης-3. Επίσης παρέχονται ανοσο-προϊόντα σύζευξης, διπλά-ειδικά μόρια και φαρμακευτικές συνθέσεις που περιλαμβάνουν τα αντισώματα Γλυπικάνης-3. Αποκαλύπτονται μέθοδοι για ανίχνευση Γλυπικάνης-3, καθώς επίσης μέθοδοι για θεραπεία διαφόρων καταστάσεων σχετικών με Γλυπικάνη-3, συμπεριλαμβανομένου ηπατοκυτταρικού καρκίνου.
CY20161100174T 2007-07-17 2016-03-01 Μονοκλωνικα αντισωματα εναντι γλυπικανης-3 CY1117236T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95984507P 2007-07-17 2007-07-17
EP08796249.4A EP2178921B1 (en) 2007-07-17 2008-07-17 Monoclonal antibodies against glypican-3

Publications (1)

Publication Number Publication Date
CY1117236T1 true CY1117236T1 (el) 2017-04-05

Family

ID=39874207

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100174T CY1117236T1 (el) 2007-07-17 2016-03-01 Μονοκλωνικα αντισωματα εναντι γλυπικανης-3

Country Status (18)

Country Link
US (2) US8680247B2 (el)
EP (1) EP2178921B1 (el)
JP (2) JP5868593B2 (el)
KR (2) KR101570252B1 (el)
CN (1) CN101815726B (el)
AU (1) AU2008275985B2 (el)
CY (1) CY1117236T1 (el)
DK (1) DK2178921T3 (el)
ES (1) ES2562790T3 (el)
HR (1) HRP20160270T1 (el)
HU (1) HUE028737T2 (el)
ME (1) ME02345B (el)
MX (1) MX2010000537A (el)
PL (1) PL2178921T3 (el)
PT (1) PT2178921E (el)
RS (1) RS54624B1 (el)
SI (1) SI2178921T1 (el)
WO (1) WO2009012394A1 (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
EP4342995A2 (en) 2006-03-31 2024-03-27 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SI2178921T1 (sl) * 2007-07-17 2016-05-31 E.R. Squibb & Sons, L.L.C. Monoklonska protitelesa proti glipikan-3
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
AU2008305851B2 (en) * 2007-09-28 2014-12-18 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
PE20120902A1 (es) * 2009-05-08 2012-08-08 Genentech Inc Anticuerpos anti-egfl7 humanizados
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
US11066483B2 (en) 2010-11-30 2021-07-20 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
EP2660328A4 (en) * 2010-12-28 2016-07-13 Chugai Pharmaceutical Co Ltd ANIMAL CELL CULTURE METHOD
EP2998320B1 (en) 2011-04-19 2018-07-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013181543A1 (en) * 2012-06-01 2013-12-05 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
CN103833852A (zh) * 2012-11-23 2014-06-04 上海市肿瘤研究所 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
LT2956173T (lt) 2013-02-14 2017-06-26 Bristol-Myers Squibb Company Tubulizino junginiai, gavimo ir panaudojimo būdai
EA201690388A1 (ru) 2013-08-14 2016-07-29 Уильям Марш Райс Юниверсити Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016036973A1 (en) 2014-09-04 2016-03-10 The Trustees Of The University Of Pennsylvania Glypican-3 antibody and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
CA2968382A1 (en) 2014-11-21 2016-05-26 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
CN104829704B (zh) * 2014-12-15 2016-08-17 河北省科学院生物研究所 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
ES2747386T3 (es) 2015-01-14 2020-03-10 Bristol Myers Squibb Co Dímeros de benzodiacepina unidos por heteroarileno, conjugados de los mismos y métodos de preparación y uso
ES2783624T3 (es) 2015-01-14 2020-09-17 Bristol Myers Squibb Co Dímeros de benzodiacepina, conjugados de los mismos y métodos de preparación y uso
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
CN105037540A (zh) * 2015-05-13 2015-11-11 北京比洋生物技术有限公司 抗磷脂酰肌醇蛋白聚糖3全人源抗体
ES2938525T3 (es) 2015-05-18 2023-04-12 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anticanceroso
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
CN107922951B (zh) * 2015-06-24 2022-01-14 学校法人庆应义塾 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体
AU2016304060B2 (en) * 2015-08-03 2022-09-29 Crage Medical Co., Limited Antibody against glypican-3 and application thereof
KR101796688B1 (ko) * 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
EP3394096A1 (en) 2015-12-21 2018-10-31 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
CN105717303A (zh) * 2016-01-29 2016-06-29 山东康力医疗器械科技有限公司 一种用荧光免疫层析法检测磷酯酰肌醇蛋白聚糖3的方法及其试剂盒
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
US20170326249A1 (en) 2016-05-10 2017-11-16 Bristol-Myers Squibb Company Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
CN106084041A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 一种全人源抗GPC3的全分子IgG抗体及其应用
AU2017301826A1 (en) 2016-07-26 2019-03-14 Tessa Therapeutics Ltd. Chimeric antigen receptor
KR102493853B1 (ko) 2016-08-19 2023-01-30 브리스톨-마이어스 스큅 컴퍼니 세코-시클로프로파피롤로인돌 화합물, 그의 항체-약물 접합체, 및 제조 및 사용 방법
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
CA3059820A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
CN116333129A (zh) 2017-05-25 2023-06-27 百时美施贵宝公司 包含经修饰的重链恒定区的抗体
CN109988240B (zh) * 2017-12-29 2022-06-28 安源医药科技（上海）有限公司 抗gpc-3抗体及其用途
EA202092747A1 (ru) 2018-05-29 2021-03-16 Бристол-Маерс Сквибб Компани Модифицированные саморазрушающиеся фрагменты для применения в пролекарствах и конъюгатах и способы применения и изготовления
CN113286808A (zh) 2018-10-23 2021-08-20 蜻蜓疗法股份有限公司 异二聚体Fc融合蛋白
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
PL3886914T3 (pl) 2018-11-30 2023-05-08 Bristol-Myers Squibb Company Przeciwciało zawierające c-końcowe rozszerzenie łańcucha lekkiego zawierające glutaminę, jego koniugaty oraz metody i zastosowania
KR20210102334A (ko) 2018-12-12 2021-08-19 브리스톨-마이어스 스큅 컴퍼니 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도
SG11202110390XA (en) * 2019-03-21 2021-10-28 Agency Science Tech & Res Composition
KR20230004746A (ko) 2020-04-22 2023-01-06 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체 fc-융합 단백질에 대한 제형, 투여 요법 및 제조 방법
TW202241947A (zh) * 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽
BR112023021557A2 (pt) * 2021-04-23 2023-12-19 Shanghai Henlius Biotech Inc Anticorpos anti-gpc3 e métodos de uso
CN113354737B (zh) * 2021-07-20 2022-11-18 广州爱思迈生物医药科技有限公司 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3426001B2 (ja) 1993-09-16 2003-07-14 東芝機械株式会社 ステージ内蔵型雰囲気室装置
EP0822830B1 (en) * 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
US20040236080A1 (en) * 2001-06-22 2004-11-25 Hiroyuki Aburatani Cell proliferation inhibitors containing anti-glypican 3 antibody
WO2004022597A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
WO2004022595A1 (ja) 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha MRL/lprマウスを用いた抗体の作製
WO2004023145A1 (ja) 2002-09-04 2004-03-18 Perseus Proteomics Inc. Ｇｐｃ3の検出による癌の診断方法
WO2004067571A1 (fr) 2003-01-30 2004-08-12 Wu, Mengchao Anticorps monoclonal contre l'hepatome humain et utilisation de celui-ci
WO2005001921A1 (ja) 2003-06-27 2005-01-06 Nec Corporation 薄膜トランジスタ、薄膜トランジスタ基板、電子機器及び多結晶半導体薄膜の製造方法
PL1674111T3 (pl) 2004-07-09 2011-04-29 Chugai Pharmaceutical Co Ltd Przeciwciała anty-glipikan 3
JP4733042B2 (ja) 2004-08-24 2011-07-27 中外製薬株式会社 抗グリピカン３抗体を用いたアジュバント療法
CN101068836B (zh) 2004-10-26 2013-08-14 中外制药株式会社 糖链改变的抗磷脂酰肌醇聚糖3抗体
EP2336174B8 (en) * 2005-03-14 2015-09-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Human monoclonal antibodies against Hendra and Nipah viruses
HUE026039T2 (en) * 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
US7744800B2 (en) 2006-01-06 2010-06-29 Molded Fiber Glass Companies Method and apparatus for controlling the stacking height of stackable products during compression molding off stops
KR20150067395A (ko) * 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
SI2178921T1 (sl) 2007-07-17 2016-05-31 E.R. Squibb & Sons, L.L.C. Monoklonska protitelesa proti glipikan-3
US8852599B2 (en) * 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use

Also Published As

Publication number Publication date
ES2562790T3 (es) 2016-03-08
US20140186892A1 (en) 2014-07-03
JP2010533498A (ja) 2010-10-28
MX2010000537A (es) 2010-03-25
US9217033B2 (en) 2015-12-22
US8680247B2 (en) 2014-03-25
AU2008275985B2 (en) 2013-09-19
AU2008275985A1 (en) 2009-01-22
SI2178921T1 (sl) 2016-05-31
RS54624B1 (en) 2016-08-31
KR20150038732A (ko) 2015-04-08
WO2009012394A1 (en) 2009-01-22
EP2178921B1 (en) 2016-01-06
EP2178921A1 (en) 2010-04-28
DK2178921T3 (en) 2016-04-04
US20100209432A1 (en) 2010-08-19
PL2178921T3 (pl) 2016-06-30
KR101570252B1 (ko) 2015-11-19
JP5868593B2 (ja) 2016-02-24
CN101815726B (zh) 2013-04-03
ME02345B (me) 2016-08-31
PT2178921E (pt) 2016-03-23
KR101527342B1 (ko) 2015-06-09
KR20100056467A (ko) 2010-05-27
HRP20160270T1 (hr) 2016-05-06
CN101815726A (zh) 2010-08-25
HUE028737T2 (en) 2017-01-30
JP2014236734A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
CY1117236T1 (el) Μονοκλωνικα αντισωματα εναντι γλυπικανης-3
CY1118949T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
CY1119539T1 (el) Πληρως ανθρωπινα αντισωματα ειδικα για to cadμ1
CY1123609T1 (el) Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
MX2009005776A (es) Anticuerpos humanos que se enlazan al cd 22 y sus usos.
MX2009006277A (es) Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
MY150246A (en) Alpha 5 - beta 1 antibodies and their uses
TN2011000524A1 (en) Antibodies specific to cadherin -17
EA200870020A1 (ru) Человеческие моноклональные антитела против о8е
WO2006076691A3 (en) Irta-2 antibodies and their uses
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
CY1119410T1 (el) Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi)
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
IN2012DN00640A (el)
WO2012054084A3 (en) Antibodies
CY1119351T1 (el) Αντισωματα σε adp-ριβοζυλ κυκλαση 2
WO2006116192A3 (en) Irta-1 antibodies and their uses
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
CY1113958T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1